Trial ID or NCT#
This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.
A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
- - Must have relapsed or refractory Chronic Lymphocytic Leukemia (CLL), received no more than 5 prior myelosuppressive/chemotherapy regimens and must be a candidate for treatment with either Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR); - Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of /=1000/mcL, Platelets>/= 100,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening),Hemoglobin >/= 9.0 g/dL.
- - Subject has history or is clinically suspicious for cancer-related Central Nervous System disease; - Has history of severe allergic or anaphylactic reactions to human, humanized, chimeric or murine monoclonal antibodies; - Has undergone an allogeneic stem cell transplant; Exhibits evidence of other uncontrolled condition(s) including, but not limited to: uncontrolled systemic infection, diagnosis of fever and neutropenia within 1 week prior to study drug administration; - Has underlying, predisposing condition of bleeding or currently exhibits signs of bleeding; Has a recent history of non-chemotherapy induced thrombocytopenic associated bleeding; - Currently receiving or requires anticoagulation therapy; - Has active immune thrombocytopenic purpura (ITP) or a history of being refractory to platelet transfusions (within 1 year prior to 1st dose of study drug); - Has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis.
Contact us to find out if this trial is right for you.
Cancer Clinical Trials Office
About this Clinical Trial
Your Message Will Go ToCancer Clinical Trials Office
To:Cancer Clinical Trials Office
Go Back To The Trial